PeterBulkeleyLangmuirMD

Pediatric Hematology & Oncology • Collegeville, PA

Physician

Join to view full profile

Are you Dr. Langmuir?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 17 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
1250 S Collegeville Rd
Collegeville, PA 19426
Phone+1 215-805-3112
Is this information wrong?

Summary

Dr. Peter Langmuir, MD is a pediatric hematologist/oncologist in Collegeville, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania.

Education & Training

Yale School of MedicineClass of 1994

Certifications & Licensure

PA State Medical License 1996 - 2024
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Publications & Presentations

PubMed

31 citations
JAK inhibitors and COVID-19.
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan N Constantinescu> ;Journal for Immunotherapy of Cancer. 2022 Apr 1
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomi...
Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, Garcia JA, Protheroe A, Tammela TL, Elliott T, Mattila L, Aspegren J, Vuorela A, Langmuir P, Mustonen M> ;Lancet Oncol.. 2014-08-01
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: ...
Lee JS, Hirsh V, Park K, Qin S, Blajman CR, Perng R, Chen Y, Emerson L, Langmuir P, Manegold C> ;J. Clin. Oncol.. 2012-04-01
Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squam...
Papadimitrakopoulou V, Heymach J, Frank SJ, Myers J, Lin H, Tran HT, Chen C, Hirsch FR, Langmuir PB, Vasselli JR, Lippman SM, Raben D> ;J. Clin. Oncol.. 2011-05-20
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III...
Herbst RS, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy SJ, Johnson BE> ;J. Clin. Oncol.. 2009-06-20
Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, doub...
Natale RB, Thongprasert S, Greco FA, Thomas M, Tsai CM, Sunpaweravong P, Ferry D, Langmuir P, Rowbottom JA, Goss GD> ;J. Clin. Oncol.. 2009-05-20
Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III ...
De Boer R, Arrieta Ó, Gottfried M, Blackhall FH, Raats J, Yang CH, Langmuir P, Milenkova T, Read J, Vansteenkiste J> ;J. Clin. Oncol.. 2009-05-20
Phase I evaluation of vandetanib with radiation therapy (RT) ± cisplatin in previously untreated advanced head and neck squamous cell carcinoma (HNSCC).
Papadimitrakopoulou V, Frank SJ, Blumenschein GR, Chen C, Kane M, Cohen EE, Langmuir P, Krebs AD, Lippman SM, Raben D> ;J. Clin. Oncol.. 2009-05-20
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III...
Herbst RS, Sun Y, Korfee S, Germonpré P, Saijo N, Zhou C, Wang J, Langmuir P, Kennedy SJ, Johnson BE> ;J. Clin. Oncol.. 2009-05-20
Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC.
Heymach JV, Hanrahan EO, Mann H, Langmuir P, Natale RB, Johnson BE, Herbst RS, Ryan AJ> ;J. Clin. Oncol.. 2008-05-20
A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer.
Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch W, Schlumberger M> ;J. Clin. Oncol.. 2006-06-20
Prevalence of pre-existing conditions and incidence of new medical conditions after diagnosis of non-small cell lung cancer.
Koo LC, De Lissovoy G, Hanna NL, Lyidick E, Lambe M, Higenbottam T, Steinberg MH, Langmuir P> ;J. Clin. Oncol.. 2006-06-20
Evaluation of the role of body-surface-area dose adjustment of ZD6126, a novel vascular-targeting agent.
Oliver R, Wheeler C, Langmuir P, Melezinek I, Stone A> ;J. Clin. Oncol.. 2004-07-15
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.
Kishimoto, K., Sandner, S., Imitola, J., Sho, M., Li, Y., Langmuir, P.B., Rothstein, D.M., Strom, T.B., Turka, L.A., Sayegh, M.H.> ;J Clin Invest. 2002 Jun
Acute myeloid leukaemia in children.
Langmuir, P. B., Aplenc, R., Lange, B. J.> ;Best Pract Res Clin Haematol. 2001 Mar
Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question.
Suchin, E. J., Langmuir, P. B., Palmer, E., Sayegh, M. H., Wells, A. D., Turka, L. A.> ;J Immunol. 2001 Jan 15
PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells.
Guerriero, A., Langmuir, P. B., Spain, L. M., Scott, E. W.> ;Blood. 2000 Feb 1
Bone marrow abnormalities in the non-obese diabetic mouse.
Langmuir, P. B., Bridgett, M. M., Bothwell, A. L., Crispe, I. N.> ;Int Immunol. 1993 Feb
Vandetanib for the treatment of thyroid cancer.
Langmuir, P. B., Yver, A.> ;Clin Pharmacol Ther. 2012 Jan
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., Read, J., Langmuir, P., Ryan, ...> ;J Clin Oncol. 2012 Jan 10
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
Natale, R. B., Thongprasert, S., Greco, F. A., Thomas, M., Tsai, C. M., Sunpaweravong, P., Ferry, D., Mulatero, C., Whorf, R., Thompson, J., Barlesi, F., Langmuir, P.,...> ;J Clin Oncol. 2011 Mar 10
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
de Boer, R. H., Arrieta, Ó., Yang, C. H., Gottfried, M., Chan, V., Raats, J., de Marinis, F., Abratt, R. P., Wolf, J., Blackhall, F. H., Langmuir, P., Milenkova, T., R...> ;J Clin Oncol. 2011 Mar 10
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil, A., Martin, P., Smith, R., Oliver, S., Langmuir, P., Read, J., Molz, K. H.> ;Clin Pharmacokinet. 2010 Sep
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3...
Herbst, R. S., Sun, Y., Eberhardt, W. E., Germonpré, P., Saijo, N., Zhou, C., Wang, J., Li, L., Kabbinavar, F., Ichinose, Y., Qin, S., Zhang, L., Biesma, B., Heymach, ...> ;Lancet Oncol. 2010 Jul
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
Hanrahan, E. O., Lin, H. Y., Kim, E. S., Yan, S., Du, D. Z., McKee, K. S., Tran, H. T., Lee, J. J., Ryan, A. J., Langmuir, P., Johnson, B. E., Heymach, J. V.> ;J Clin Oncol. 2010 Jan 10
Join now to see all

Press Mentions

Incyte Et MorphoSys Annoncent La Validation De La Demande D'autorisation De Mise Sur Le Marché Européen Du TafasitamabMay 21st, 2020
Incyte: And MorphoSys Announce the Validation of the Request for Authorization to Market Tafasitamab on the European MarketMay 21st, 2020
MorphoSys Und Incyte Geben Die Validierung Des Europäischen Zulassungsantrags Für Tafasitamab BekanntMay 20th, 2020
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member